Johnson & Johnson (NYSE: JNJ) reported third-quarter 2020 financial results before the opening bell on Tuesday. The pharmaceutical giant reported a 2% increase in Q3 revenues to $21.1 billion, beating the Wall Street consensus. Earnings of $2.20 per share were also stronger than what analysts had anticipated.
JNJ shares were down 1.6% immediately following the announcement. The stock has gained 4% since the beginning of this year.
“Our third-quarter results reflect solid performance and positive trends across Johnson & Johnson, powered by better-than-expected procedure recovery in Medical Devices, growth in Consumer Health, and continued strength in Pharmaceuticals,” CEO Alex Gorsky said in a statement.
Prior performance
4Q19 
3Q19
Most Popular
CCL Earnings: Highlights of Carnival Corporation’s Q4 2025 results
Cruise operator Carnival Corporation & plc (NYSE: CCL) on Friday reported an increase in revenue and adjusted earnings for the fourth quarter of fiscal 2025. Earnings topped analysts' expectations. Revenues
Lamb Weston (LW) Q2 2026 Earnings: Key financials and quarterly highlights
Lamb Weston Holdings, Inc. (NYSE: LW) reported its second quarter 2026 earnings results today. Net sales inched up 1% year-over-year to $1.62 billion. Net sales at constant currency remained flat.
Paychex reports higher Q2 FY26 revenue and earnings; EPS beats estimates
Paychex Inc. (NASDAQ: PAYX) on Friday reported stronger-than-expected adjusted earnings for the second quarter of fiscal 2026. Revenues grew 18% year-over-year. The Rochester-based human capital management solutions provider reported revenues
